ADC Therapeutics, Sobi Ink European Licensing Pact For Lymphoma Drug

ADC Therapeutics SA  (NYSE: ADCT ) has entered into an exclusive license agreement  with Swedish Orphan Biovitrum AB  (OTC: BIOVF ) for the development and commercialization of Zynlonta for all hematologic and solid tumor indications outside of the U.S., Greater China, Singapore, and Japan. ADC Therapeutics and Sobi intend to make Zynlonta available following a regulatory decision ... Full story available on Benzinga.com